Ioannis Vizirianakis
Ioannis Vizirianakis
Associate Professor of Molecular Pharmacology and Pharmacogenomics
Verified email at pharm.auth.gr - Homepage
Title
Cited by
Cited by
Year
Erythropoiesis: model systems, molecular regulators, and developmental programs
AS Tsiftsoglou, IS Vizirianakis, J Strouboulis
IUBMB life 61 (8), 800-830, 2009
2202009
Mechanisms involved in the induced differentiation of leukemia cells
AS Tsiftsoglou, IS Pappas, IS Vizirianakis
Pharmacology & therapeutics 100 (3), 257-290, 2003
2012003
Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver
A Arora, K Seth, Y Shukla
Carcinogenesis 25 (6), 941-949, 2004
1252004
Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes
IS Vizirianakis
Nanomedicine: Nanotechnology, Biology and Medicine 7 (1), 11-17, 2011
932011
Controlled release of 5-fluorouracil from microporous zeolites
M Spanakis, N Bouropoulos, D Theodoropoulos, L Sygellou, S Ewart, ...
Nanomedicine: Nanotechnology, Biology and Medicine 10 (1), 197-205, 2014
772014
Lipid-like self-assembling peptide nanovesicles for drug delivery
DG Fatouros, DA Lamprou, AJ Urquhart, SN Yannopoulos, IS Vizirianakis, ...
ACS applied materials & interfaces 6 (11), 8184-8189, 2014
702014
Biocompatible Zr-based nanoscale MOFs coated with modified poly (ε-caprolactone) as anticancer drug carriers
M Filippousi, S Turner, K Leus, PI Siafaka, ED Tseligka, M Vandichel, ...
International journal of pharmaceutics 509 (1-2), 208-218, 2016
652016
Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine
IS Vizirianakis
European Journal of Pharmaceutical Sciences 15 (3), 243-250, 2002
622002
Microfluidic transport in microdevices for rare cell capture
JP Smith, AC Barbati, SM Santana, JP Gleghorn, BJ Kirby
Electrophoresis 33 (21), 3133-3142, 2012
452012
Electrosprayed mesoporous particles for improved aqueous solubility of a poorly water soluble anticancer agent: in vitro and ex vivo evaluation
E Sayed, C Karavasili, K Ruparelia, R Haj-Ahmad, G Charalambopoulou, ...
Journal of Controlled Release 278, 142-155, 2018
422018
Synthesis, molecular structure determination, and antitumor activity of platinum (II) and palladium (II) complexes of 2-substituted benzimidazole.
S Mylonas, A Valavanidis, K Dimitropoulos, M Polissiou, AS Tsiftsoglou, ...
Journal of inorganic biochemistry 34 (4), 265-275, 1988
411988
Modified chitosan coated mesoporous strontium hydroxyapatite nanorods as drug carriers
M Filippousi, PI Siafaka, EP Amanatiadou, SG Nanaki, M Nerantzaki, ...
Journal of Materials Chemistry B 3 (29), 5991-6000, 2015
362015
Dominant-negative E-cadherin alters adhesion and reverses contact inhibition of growth in breast carcinoma cells
IS Vizirianakis, YQ Chen, SS Kantak, AS Tsiftsoglou, RH Kramer
International journal of oncology 21 (1), 135-144, 2002
362002
Development of new drug delivery system based on ordered mesoporous carbons: characterisation and cytocompatibility studies
C Karavasili, EP Amanatiadou, L Sygellou, DK Giasafaki, TA Steriotis, ...
Journal of Materials Chemistry B 1 (25), 3167-3174, 2013
352013
Development of a nanoporous and multilayer drug-delivery platform for medical implants
V Karagkiozaki, E Vavoulidis, PG Karagiannidis, M Gioti, DG Fatouros, ...
International journal of nanomedicine 7, 5327, 2012
352012
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives
IS Vizirianakis, M Chatzopoulou, ID Bonovolias, I Nicolaou, ...
Journal of medicinal chemistry 53 (19), 6779-6810, 2010
332010
Desmoglein-3/γ-catenin and E-cadherin/-catenin differential expression in oral leukoplakia and squamous cell carcinoma
M Kyrodimou, D Andreadis, A Drougou, EP Amanatiadou, L Angelis, ...
Clinical oral investigations 18 (1), 199-210, 2014
312014
Expression of ribosomal protein S5 cloned gene during differentiation and apoptosis in murine erythroleukemia (MEL) cells.
IS Vizirianakis, IS Pappas, D Gougoumas, AS Tsiftsoglou
Oncology research 11 (9), 409-419, 1999
301999
Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice
IS Vizirianakis
Current drug delivery 1 (1), 73-80, 2004
282004
The developmental program of murine erythroleukemia cells
AS Tsiftsoglou, IS Pappas, IS Vizirianakis
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 13…, 2003
282003
The system can't perform the operation now. Try again later.
Articles 1–20